行业动态

Industry Dynamic

首页 > 行业动态 > 伯桢新闻
伯桢生物与药明生物宣布建立战略合作
发布时间:2023-05-09

伯桢生物与和药明生物宣布建立战略合作

 

bioGenous Technologies and WuXi Biologics Announce Strategic Development and Manufacturing Partnership

(*Please scroll down for English news.)

 

中国苏州 

2023年4月26日

 

2023年4月26日,伯桢生物与全球领先的生物制药技术平台公司药明生物签署战略合作协议,共同宣布在类器官上游GMP原料工艺开发和生产领域开展战略合作。

 

图片

▲伯桢生物联合创始人、研发总监倪超博士(左)、药明生物副总裁、蛋白质科学部负责人吴健生博士(右)

Dr. Chao Ni, Vice President and R&D Director of bioGenous Biotechnologies (left), Dr. Jiansheng Wu, Vice President of WuXi Biologics and Head of the Protein Science Department (right)

 
此次战略合作,将借助药明生物高水平的生物制药以及蛋白质科学平台,以及伯桢生物在类器官底层技术创新和医药应用等领域的优势,携手开发类器官上游GMP原料规模化生产工艺,实现“研发-工艺标准化-GMP生产”全环节自主可控。双方合作成果将进一步推动类器官技术医药标准化与产业化应用,助力中国乃至全球生物医药产业创新提速。

 

图片

 

倪超博士在签约分享环节表示:“非常荣幸能在现场百余位嘉宾以及苏州工业园区领导的见证下与药明生物签署战略合作。类器官技术作为生物医药领域的革命性前沿技术拥有广阔的发展前景和产业需求。在药物研发过程中,类器官凭借高度仿生人体组织器官的优势,已在小分子药物、蛋白抗体类药物、偶联药物、细胞和基因药物的临床前评价中展现出独特优势。但作为一种新兴的革命性模型,类器官技术依然处于不断完善和标准化的过程中,特别是以细胞因子、培养原料等为代表的类器官上游原料尚未完全实现GMP标准化。前期伯桢生物和药明生物的科学家已经合作开发了一批高活性、高稳定性的蛋白原料,作为合作者深切感受到了药明生物在蛋白科学领域的成熟经验以及超高技术水平。这次战略合作,双方将进一步扩大合作范围,充分发挥伯桢生物在类器官上游技术平台的优势和经验,以及药明生物在蛋白纯化工艺开发、制剂生产以及创新生物药发现领域的巨大优势,加快类器官技术革新与产业化应用。未来伯桢生物将与药明生物并肩前行,共创未来,不断推进行业进步,积极为生物医药事业发展注入能量。”

 

签约仪式在药明生物第二届蛋白质科学研讨会-苏州站会议现场进行,双方企业代表以及苏州工业园区管委会相关领导出席并见证此次签约。

 

 

关于伯桢生物

伯桢生物致力于为生物医学科学研究、药物研发和临床精准医疗提供标准化、模块化、自动化类器官产品和技术支持。公司秉承“引领医药创新,共享模型价值”的愿景,以国际一流的研发科技人才为核心,以“全球领先类器官模型平台”为使命,坚持优质和高效的服务,切实提升客户新药研发效率和基础研究能力,让好药更早惠及百姓。

 

关于药明生物

药明生物(股票代码:2269.HK)是一家全球领先的合同研究、开发和生产(CRDMO)公司。公司通过开放式、一体化生物制药能力和技术赋能平台,提供全方位的端到端服务,帮助合作伙伴发现、开发及生产生物药,实现从概念到商业化生产的全过程,加速全球生物药研发进程,降低研发成本,造福病患。

 

 

 

 

bioGenous Technologies and WuXi Biologics Announce Strategic Development and Manufacturing Partnership

 

SUZHOU,CHINA 

April 26, 2023

 

On April 26, 2023, bioGenous Technologies signed a strategic partnership agreement with WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) company, to collaborate in the development and manufacture of upstream GMP-grade raw materials for organoid culture. 

 

This strategic collaboration will leverage the advanced biopharmaceutical and protein science platforms of WuXi Biologics as well as the novel biomedical innovations and application of organoid technology platforms of bioGenous Technologies to jointly develop a large-scale production line for upstream GMP-grade raw materials for organoid culture. This collaboration is aimed at realizing an integrated system of the whole process from research and development to process standardization and GMP production. This collaboration will further promote the standardization and application of organoid technology in biologics, and accelerate innovations in both local and international biopharmaceutical industries.

 

In his comment, Dr. Ni expressed great optimism about the prospect of this strategic partnership with WuXi Biologics in championing cutting-edge innovations in organoid technology. Organoid technology, a revolutionary technology in the field of biomedicine, has great prospects for development and industrial application. In drug development, organoids have shown unique advantages in the preclinical evaluation of small molecule drugs, protein antibody drugs, conjugated drugs, and cell and gene drugs owing to the high mimicry of the primary human tissue or organ. However, as an emerging revolutionary model, organoid technology requires continuous optimization and standardization, especially since most of the upstream proteins needed for organoid cultures, such as cytokines and growth factors lack GMP standards. In the past, bioGenous Technologies and WuXi Biologics have previously cooperated in the development of highly stable proteins with superior activity. The current strategic coop

分享到微信